<DOC>
	<DOCNO>NCT00711035</DOCNO>
	<brief_summary>This trial design evaluate feasibility , safety efficacy closely HLA-matched multivirus specific CTL line ( CHM-CTLs ) HSCT patient EBV , CMV adenovirus infection persistent despite standard therapy . The primary objective study assess safety feasibility administer CTLs . Survival data collect ask transplant center submit routine Transplant Essential Data form send Stem Cell Transplant Outcomes Database 100 day 1 year include data survival status outcome measure .</brief_summary>
	<brief_title>Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes ( CTL )</brief_title>
	<detailed_description>Patients may screen study entry persistent disease despite standard therapy define inclusion criterion . At stage search do available line . Lines generate HSCT donor consent use CTLs require recipient research normal donor . All donor screen deem eligible transplant donor . We also manufacture additional line goal cover common HLA type consult NMDP determine HLA type would desirable . Additional donor screen transplant donor center physician must deem eligible line manufacture . CTL Lines : We use trivirus specific CTL line generate described previously . Generation trivirus-specific CTL line require generation several different component PBMC . The CTL line derive donor peripheral blood T cell , multiple stimulation antigen-presenting cell ( APCs ) present CMV , EBV adenovirus antigens expansion interleukin-2 ( IL-2 ) . The APCs use stimulate expand CMV-specific T cell derive patient mononuclear cell B lymphocytes . To initiate trivirus-specific CTL line , PBMC transduce adenovirus vector ( Ad5f35-pp65 ) express immunodominant antigen CMV , pp65 . The monocyte fraction PBMC express present CMV-pp65 peptide epitopes CMV-specific T cell fraction PBMC , virion protein adenovirus vector process present adenovirus-specific T cell fraction . To expand trivirus -specific T cell use EBV-transformed B lymphoblastoid cell line ( EBV-LCLs ) transduce Ad5f35-pp65 . This transduction allow EBV-LCLs present CMV-pp65 adenovirus virion peptide T cell well endogenously express EBV antigen . EBV-LCLs derived PBMC-B lymphocytes infection clinical grade , laboratory strain Epstein-Barr virus ( EBV ) . About 5 x 10^6 PBMC , 5 10 mLs blood require generate EBV-LCL At end CTL culture period , frequency T cell specific virus determine use tetramer reagent available . To test functional antigen specificity CTL use overlap peptide library pp65 adenovirus hexon autologous allogeneic LCLs Elispot assay perform cytotoxicity assay use unmodified PHA blast LCLs untransduced transduced Adhexon CMVpp65 pepmix OR LCL transduce Ad5f35-null Ad5f35-pp65 . Some line aliquot send characterization NIH Drs Melenhorst Barrett develop assay predict alloreactivity examine virus antigen-specific T cell use extensive panel activate T cell antigen present cell ( T-APC ) . These line label component number subject identifier . The CTL line also check identity , phenotype sterility , cryopreserved prior administration accord SOP . Release criterion administer CTL patient include viability &gt; 70 % , negative culture bacteria fungi least 7 day , endotoxin test less equal 5EU/ml , negative result Mycoplasma , &lt; 2 % CD19 positive B cell , &lt; 2 % CD14 positive monocyte ( &lt; 2 % CD83 positive cell Dendritic cell use stimulators ) HLA identity . No Matched CTL Line Available : If match line available patient register feasibility approach assess eventual outcome also collect . CTL Line Available Patient Status Changes : Patients clinical course change screen infusion give CTL follow eventual outcome . Survival data collect ask transplant center submit routine Transplant Essential Data form send Stem Cell Transplant Outcomes Database 100 day 1 year include data survival status outcome measure . Criteria Selection CTL Line : In general line match high number HLA loci select . Matching allele level prefer antigen level accept HLA-A HLA-B . However consideration also give type infection activity line virus . For example patient adenovirus infection line match 2 locus recognition adenovirus mediate antigen would preferable line match 3 loci demonstrate activity adenovirus . The protocol chair discus case principal investigator center determine optimal CTL line patient . If one line match insufficient cell cover additional infusion second CTL line reserve event additional infusion warrant . Patients partial response eligible receive additional dose . Premedications : Patients premedicated Benadryl 1mg/kg ( max 50 mg ) IV Tylenol 10 mg/kg ( max 650 mg ) PO . Patients monitor accord institutional standard administration blood product minimum monitor accord : • Patients remain clinic least one hour • Patients remain continuous pulse oximetry least 30 minute • Vital sign monitor end infusion 30 60 minute Supportive Care : Patients receive supportive care acute chronic toxicity , include blood component antibiotic , intervention appropriate . If patient partial response eligible receive 4 additional dos minimum 2 week interval meet eligibility criterion subsequent line . These dos would come original infused line sufficient vial available may come another line insufficient cell original line . Follow-up Assessments : The timing follow-up visit base date CTL infusion . If patient multiple CTL dose schedule reset begin follow relates last CTL dose . Follow occur 7 day , 14 day , 21 day , 28 day , 42 day , 90 day , 180 day , 365 day ( +/- 2 day Week 8 , +/- 14 day Days 90 , 120 , +/- 28 day 6 12 month , post-enrollment.. ) The following assessment consider standard-of-care unless identify `` * `` : Pre-Infusion : 1 . History physical exam include height weight 2 . Viral load EBV , adenovirus , CMV 3 . Biopsy disease site , appropriate 4 . Imaging study , appropriate 5 . Complete acute GVHD stag grade information include assessment rash , diarrhea , nausea/vomiting , weight liver function test 6 . CBC differential , platelet count 7 . Liver function test ( bilirubin , alkaline phosphatase , AST , ALT ) plus creatinine 8 . Tacrolimus/cyclosporine level 9 . * Samples laboratory study Post-Infusion : 1 . Viral load CMV , EBV , adenovirus weekly 1 , 2 , 3 , 4 6 week 3 , 6 12 month . 2 . Complete acute GVHD stag grade information include assessment rash , diarrhea , nausea/vomiting , weight liver function test weekly Day 45 3 . Chronic GVHD evaluation ( present ) 3 , 6 , 9 , 12 month 4 . CBC differential platelet count 1 , 2 , 3 , 4 , 6 week . 5 . Infusion related toxicity within 24 hour toxicity evaluation weekly Day 30 acute GVHD Day 45 6 . Steroid dose weekly Day 42 , 3 , 6 9 month 7 . * Samples laboratory study Days 0 , 14 , 28 90 8 . Infections Day 42 3 , 6 12 month Ancillary laboratory study include : 1 ) Assessment virus-specific immunity base CTL level measure ELISPOT assay tetramer assay . 2 ) Persistence infuse T cell base PCR non-shared antigen Reporting Patient Deaths : The Recipient Death Information must enter web-based data entry system within 24 hour knowledge patient 's death . If cause death unknown time , need recorded time . However , cause death determine , form must update . Donor Evaluation : - Complete history physical examination - CBC , platelet , differential - Total protein , albumin , total bilirubin , alkaline phosphatase , ALT , AST , - HIV-1 antibody , HIV-2 antibody , HIV NAT , HTLV-1/2 antibody , HBsantigen , HBc antibody , HCV NAT , CMV antibody , RPR , West Nile virus NAT , Chagas test - ABO Rh type - When evaluation complete , Transplant Physician note recipient 's donor 's medical record test evaluate , donor acceptable .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Adenoviridae Infections</mesh_term>
	<mesh_term>Epstein-Barr Virus Infections</mesh_term>
	<criteria>INCLUSION CRITERIA : Pts eligible follow type allogeneic transplant CMV , adenovirus EBV infection persistent standard therapy ( define ) . 1 . Prior myeloablative nonmyeloablative allogeneic hematopoietic stem cell transplant use either bone marrow , peripheral blood stem cell single double cord blood within 18 month . 2 . CMV , adenovirus EBV infection persistent despite standard therapy 1 . For CMV infection : i.Pts CMV disease : define demonstration CMV biopsy specimen visceral site ( culture histology ) detection CMV culture direct fluorescent antibody stain bronchoalveolar lavage fluid presence new change pulmonary infiltrates OR ii . Failure antiviral therapy : define continue presence pp65 antigenemia ( &gt; 1+ cell/100,000 cell ) DNAemia ( define reference lab perform PCR assay usually &gt; 400 copies/ml ) least 7 day antiviral therapy OR iii . Relapse antiviral therapy define recurrence either pp65 antigenemia DNAemia least 2 week antiviral therapy iv . For CMV infection , standard therapy define 7 day therapy Ganciclovir , Foscarnet Cidofovir patient disease recurrence 14 day therapy 2 . For EBV infection : i. EBV infection define : 1 . Biopsy proven lymphoma EBV genome detect tumor cell immunocytochemistry situ PCR OR 2 . Or clinical imaging finding consistent EBV lymphoma elevate EBV viral load peripheral blood . ii . For EBV infection , standard therapy define rituximab give 375mg/m^2 patient 14 dos CD20+ve tumor iii . Failure define : 1 . There increase less 50 % response sit disease EBV lymphoma OR 2 . There rise fall le 50 % EBV viral load peripheral blood site disease 3 . For adenovirus infection disease : i. Adenovirus infection define presence adenoviral positivity detect PCR , DAA culture ONE site stool , blood , urine , nasopharynx OR ii . Adenovirus disease define presence adenoviral positivity detect culture two site stool blood urine nasopharynx iii . Standard therapy define 7 day therapy Cidofovir ( renal function permit agent give ) iv . Failure define rise fall le 50 % viral load peripheral blood site disease measure PCR quantitative assay ) 3 . Pts multiple CMV , EBV Adenovirus infection eligible give infection persistent despite standard therapy define . Patients multiple infection one persistent infection one control infection eligible enroll . 4 . Clinical status enrollment allow taper steroid le 0.5 mg/kg/day prednisone . 5 . Written informed consent patient , parent guardian . 6 . Negative pregnancy test female patient applicable ( childbearing potential receive reduced intensity condition regimen ) . The informed consent process begin recognition subject eligibility consent obtain per institutional practice study therapy initiate . Subjects initially sign screen consent enable search make line . If line available sign treatment consent . Up 4 additional dos administer partial response obtain patient meet eligibility criterion subsequent infusion . The minimum interval subsequent infusion 2 week . Donors eligible meet eligibility criterion blood donor history exam transplant donor physician negative infectious disease test . EXCLUSION CRITERIA : For initial CTL subsequent infusion : 1 . Patients receive ATG , Campath immunosuppressive monoclonal antibody within 28 day screen enrollment . 2 . Patients uncontrolled infection . For bacterial infection , patient must receive definitive therapy sign progress infection 72 hour prior enrollment . For fungal infection patient must receive definitive systemic antifungal therapy sign progress infection 1 week prior enrollment . Progressing infection define hemodynamic instability attributable sepsis new symptom , worsen physical sign radiographic finding attributable infection . Persisting fever without sign symptom interpret progress infection . 3 . Patients receive donor lymphocyte infusion ( DLI ) within 28 day . 4 . Patients active acute GVHD grade IIIV . 5 . Active uncontrolled relapse malignancy Donors ineligible meet eligibility criterion blood donor donor questionnaire positive infectious disease test test outline inclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>CMV</keyword>
	<keyword>Adenovirus</keyword>
	<keyword>EBV</keyword>
	<keyword>non-myeloablative transplant</keyword>
	<keyword>Prior allogeneic hematopoietic stem cell transplant</keyword>
</DOC>